Related Experiment Videos
Ligand-targeted therapeutics in anticancer therapy
1Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada T6G 2H7. terry.allen@ualberta.ca
Nature Reviews. Cancer
|October 3, 2002
Summary
Targeted cancer therapies improve treatment selectivity by attaching anti-cancer drugs to antibodies that bind to tumor cells. This approach enhances drug delivery to cancer cells while minimizing damage to healthy tissues, reducing side effects.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Cancer treatments like chemotherapy and radiotherapy cause severe side effects due to toxicity to normal cells.
- Lack of selectivity in current therapies limits their efficacy and patient tolerance.
- Improving the targeted delivery of anti-cancer agents is crucial for better treatment outcomes.
Purpose of the Study:
- To explore strategies for enhancing the selectivity of cancer therapeutics.
- To investigate the potential of ligand-targeted drug delivery systems.
Main Methods:
- Coupling cytotoxic agents to antibodies or ligands.
- Utilizing antibodies/ligands that recognize tumor-associated antigens for targeted delivery.
Main Results:
- Increased exposure of malignant cells to therapeutics.
- Reduced exposure of normal cells to therapeutics, thereby minimizing side effects.
Conclusions:
- Ligand-targeted therapeutics offer a promising strategy to improve the selectivity of cancer treatment.
- This approach can enhance therapeutic efficacy and reduce treatment-related toxicities.